Institutional members access full text with Ovid®

Share this article on:

Controversies on how diabetes is diagnosed

Malkani, Samira; DeSilva, Taniyab

Current Opinion in Endocrinology, Diabetes & Obesity: April 2012 - Volume 19 - Issue 2 - p 97–103
doi: 10.1097/MED.0b013e32835168c0
DIABETES AND THE ENDOCRINE PANCREAS I: Edited by David Harlan

Purpose of review: To evaluate the controversial aspects of diabetes diagnosis.

Recent findings: Within the past 2 years, revised guidelines for the diagnosis of diabetes have been issued which endorse the use of the hemoglobin A1C as a diagnostic test, in addition to the previously recommended tests. Updated diagnostic criteria for gestational diabetes were also published in the same period. Recent publications on the current role of oral glucose tolerance tests and diagnosis of diabetes in the acutely ill are sparse. There are new recommendations regarding the use of genetic testing and antibody testing in establishing the cause of diabetes.

Summary: The inclusion of A1C as a diagnostic test has many advantages including reproducibility of the test and convenience, but there are situations where the test is unreliable and it misses many individuals who would have been diagnosed by plasma glucose testing. The diagnostic threshold of 6.5% for the A1C remains controversial. There is still no consensus on the best approach to diagnose gestational diabetes. The role of the oral glucose tolerance test seems to be diminishing. Diagnosis of diabetes in acute illness is aided by A1C testing. Genetic and autoantibody testing in specific situations offer diagnostic and therapeutic utility.

aUniversity of Massachusetts Medical School, Worcester, Massachusetts

bLouisiana State University School of Medicine, New Orleans, Louisiana, USA

Correspondence to Samir Malkani, MD, MRCP (UK), UMass Medical School, Diabetes Center of Excellence, 55 Lake Avenue North, AC4-121, Worcester, MA 01655, USA. Tel: +1 508 856 3800; fax: +1 774 442 4668; e-mail: samir.malkani@umassmemorial.org

© 2012 Wolters Kluwer Health | Lippincott Williams & Wilkins